Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Arena third quarter net loss increases to $36.3 million

Arena Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Arena also reported earlier today top-line results from its lorcaserin Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial.

9 Nov 2010

Progenics third quarter net loss increases to $17.1 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2010.

8 Nov 2010

Solutia sells Perkalink business

Solutia Inc. announced today that it has sold its Perkalink® business and entered into a definitive agreement to sell select Primary Accelerators assets to LANXESS, a Germany-based specialty chemicals company.

8 Nov 2010

XenoPort third quarter net loss decreases to $19.9 million

XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.

8 Nov 2010

China Kanghui third quarter net revenue increases 33.9% to RMB63.6 million

China Kanghui Holdings a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced financial results for the third quarter of 2010.

8 Nov 2010

VIVUS closes sale of MUSE business to Meda

VIVUS, Inc. today announced that it has closed the sale of its MUSE business to Meda. Under the purchase agreement, Meda acquired the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.

8 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Probe Manufacturing receives $475,000 blanket purchase order from medical device manufacturing client

Probe Manufacturing, Inc., a global electronics design, manufacturing, and services company, is pleased to announce that it has secured a $475,000 blanket purchase order from a medical device manufacturing client with initial delivery starting December of 2010.

8 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

Viking Systems third quarter sales decreases 8% to $1,832,502

Viking Systems, Inc. today announced financial results for its third quarter ended September 30, 2010. The Company reported a net loss for the quarter ended September 30, 2010 of $632,565 or $0.01 per share and net loss of $1,378,865 or $0.03 per share for the nine months ended September 30, 2010.

4 Nov 2010

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

Benchmark adds Class III medical device manufacturing capabilities in Thailand

Benchmark Electronics, Inc., a leading integrated electronics manufacturing services (EMS) provider, announced its Thailand facility has successfully completed a full Quality System Inspection Technique (QSIT) audit from the Food and Drug Administration (FDA), through its premarket approval (PMA) supplement evaluation process, to manufacture Class III finished devices on behalf of large tier-one medical original equipment manufacturers (OEMs).

4 Nov 2010

Lentigen awarded $1.23M grant under Patient Protection and Affordable Care Act

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act.

4 Nov 2010

Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

Bolder BioTechnology, Inc. today announced that it has been awarded a total of $1.2 million in Qualifying Therapeutic Discovery Project Grants. Grants were awarded for qualified investments under the Qualifying Therapeutic Discovery Project Tax Credit Program, which authorized up to $1 billion in tax credits or grants to biopharmaceutical companies with 250 or fewer employees.

4 Nov 2010

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.

4 Nov 2010

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton Pharmaceuticals, Inc. today announced that it has submitted to the U.S. Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Insmed third quarter total revenues decrease to $1.8 million

Insmed Inc., a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2010.

3 Nov 2010

Cambridge Heart third quarter sales increase 21% to $793,000

Cambridge Heart, Inc., today reported results for the three and nine months ended September 30, 2010.

3 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010